Last updated on November 2019

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients


Brief description of study

The purpose of this study is to support the dose selection for future studies by evaluating efficacy and safety of different QBW251 doses in COPD patients with chronic bronchitis and a history of exacerbations, compared to placebo, when added to a triple combination therapy of LABA, LAMA and ICS with respect to trough FEV1 change from baseline after 12 weeks of treatment.

Clinical Study Identifier: NCT04072887

Find a site near you

Start Over

Novartis Investigative Site

Andalusia, AL United States
  Connect »

Novartis Investigative Site

Los Angeles, CA United States
  Connect »

Novartis Investigative Site

Westminster, CA United States
  Connect »

Novartis Investigative Site

Boulder, CO United States
  Connect »

Novartis Investigative Site

Ormond Beach, FL United States
  Connect »

Novartis Investigative Site

Winter Park, FL United States
  Connect »

Novartis Investigative Site

River Forest, IL United States
  Connect »

Novartis Investigative Site

Florence, KY United States
  Connect »

Novartis Investigative Site

New Orleans, LA United States
  Connect »

Novartis Investigative Site

Livonia, MI United States
  Connect »

Novartis Investigative Site

Saint Louis, MO United States
  Connect »

Novartis Investigative Site

Charlotte, NC United States
  Connect »

Novartis Investigative Site

Gastonia, NC United States
  Connect »

Novartis Investigative Site

Columbus, OH United States
  Connect »

Novartis Investigative Site

South Brisbane, Australia
  Connect »